🇺🇸 FDA

Intelligence Platform

Patents

Browse 263 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11161908

BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof

The Board of Regents of the University of Texas System · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11147883

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mamm

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11149321

Methods and compositions for targeted single-stranded cleavage and targeted integration

Sangamo Therapeutics, Inc. · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11130783

CD40 targeted peptides and uses thereof

Regents of the University of Minnesota · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098025

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Montelino Therapeutics Inc. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084859

Targeted mutant interferon-gamma and uses thereof

Orionis Biosciences, Inc · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11083753

Targeted replacement of endogenous T cell receptors

The Regents of the University of California · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11085022

Inflammation-targeted neutrophil granulocyte drug delivery system and use thereof

CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053495

Multi-targeted single entity conjugates

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11033584

Targeted replacement of endogenous T cell receptors

The Regents of the University of California · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11001610

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975158

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10974235

Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarbox

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954516

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947317

NaPi2b-targeted antibody-drug conjugates and methods of use thereof

Mersana Therapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10918668

Targeted disruption of T cell receptor genes using engineered zinc finger protein nuclease

Sangamo Therapeutics, Inc. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10906985

Targeted engineered interferon and uses thereof

Orionis Biosciences, Inc · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10889834

Methods and compositions for enhancing targeted transgene integration

Sangamo Therapeutics, Inc. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10881735

Phase change nanodroplet conjugates for targeted delivery

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10875893

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and me

Apellis Pharmaceuticals, Inc. · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10874610

Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics

Northwestern University · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10864270

Nanostructured carriers for guided and targeted on-demand substance delivery

The Regents of the University of California · Granted Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10849875

Cancer specific lipid targeted peptidomimetics

The Board of Regents of the University of Texas System · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10828315

Targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted